Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV000286988 | SCV000431765 | uncertain significance | Limb-girdle muscular dystrophy, recessive | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000323409 | SCV000431766 | uncertain significance | Miyoshi myopathy | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001240549 | SCV001413506 | uncertain significance | Qualitative or quantitative defects of dysferlin | 2022-09-13 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 846 of the DYSF protein (p.Ala846Thr). This variant is present in population databases (rs143632564, gnomAD 0.008%). This variant has not been reported in the literature in individuals affected with DYSF-related conditions. ClinVar contains an entry for this variant (Variation ID: 336960). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt DYSF protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Revvity Omics, |
RCV003144230 | SCV003830926 | uncertain significance | not provided | 2020-12-11 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003258773 | SCV003970129 | uncertain significance | Inborn genetic diseases | 2023-04-05 | criteria provided, single submitter | clinical testing | The c.2536G>A (p.A846T) alteration is located in exon 25 (coding exon 25) of the DYSF gene. This alteration results from a G to A substitution at nucleotide position 2536, causing the alanine (A) at amino acid position 846 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001828332 | SCV002079862 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2019-10-28 | no assertion criteria provided | clinical testing |